Improving Energy Balance in Men With Prostate Cancer
Status: | Completed |
---|---|
Conditions: | Prostate Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 19 - Any |
Updated: | 2/7/2015 |
Start Date: | September 2012 |
End Date: | October 2014 |
Exploring the Impact of Negative Energy Balance in Men With Prostate Cancer
RATIONALE: Obesity and overweight are associated with the risk of aggressive disease, and
energy balance may play a major role in prostate cancer progression.
PURPOSE: Randomized phase II trial to study the effectiveness of weight loss, via a healthy
energy-restricted diet and exercise, in slowing or preventing disease progression in
patients who have newly diagnosed prostate cancer.
energy balance may play a major role in prostate cancer progression.
PURPOSE: Randomized phase II trial to study the effectiveness of weight loss, via a healthy
energy-restricted diet and exercise, in slowing or preventing disease progression in
patients who have newly diagnosed prostate cancer.
This is a 2-arm randomized controlled feasibility trial among 40 overweight or obese men
newly diagnosed with prostate cancer who are scheduled for prostatectomy. This study will
use the presurgical period to explore the potential impact of weight loss via a healthy
energy-restricted diet and increased physical activity on circulating hormones, cytokines,
and growth factors, as well as effects on tumor biology and other clinical outcomes.
Consenting patients will be block randomized to 1-of-2 study arms: 1) a healthful diet +
exercise intervention to promote a weight loss of up to 2 pounds/week; or 2) a wait-list
control who will receive the intervention once the study period is complete. Both groups
will receive nutritional counseling during the study period to correct nutritional
deficiencies with food sources. This study will explore and contrast changes in body mass
index (BMI) observed over the study period (minimum of 3.5 weeks) in the intervention vs.
wait-list control arms, and also monitor changes in body composition, energy intake and
physical activity; these changes will be studied in relation to the following endpoints: a)
changes in select circulating biomarkers and gene expression related to cancer progression,
hormonal status, inflammation and other energy-related factors; b) rates of tumor
proliferation and apoptosis; c) tumor immunohistochemical markers of insulin receptor,
vascular endothelial growth factor (VEGF), AKT, and nuclear factor
kappa-light-chain-enhancer of activated B cells (NFkB); and d) functional and health-related
outcomes, i.e., side-effects and medical outcomes, quality of life (QoL), and functional
status.
newly diagnosed with prostate cancer who are scheduled for prostatectomy. This study will
use the presurgical period to explore the potential impact of weight loss via a healthy
energy-restricted diet and increased physical activity on circulating hormones, cytokines,
and growth factors, as well as effects on tumor biology and other clinical outcomes.
Consenting patients will be block randomized to 1-of-2 study arms: 1) a healthful diet +
exercise intervention to promote a weight loss of up to 2 pounds/week; or 2) a wait-list
control who will receive the intervention once the study period is complete. Both groups
will receive nutritional counseling during the study period to correct nutritional
deficiencies with food sources. This study will explore and contrast changes in body mass
index (BMI) observed over the study period (minimum of 3.5 weeks) in the intervention vs.
wait-list control arms, and also monitor changes in body composition, energy intake and
physical activity; these changes will be studied in relation to the following endpoints: a)
changes in select circulating biomarkers and gene expression related to cancer progression,
hormonal status, inflammation and other energy-related factors; b) rates of tumor
proliferation and apoptosis; c) tumor immunohistochemical markers of insulin receptor,
vascular endothelial growth factor (VEGF), AKT, and nuclear factor
kappa-light-chain-enhancer of activated B cells (NFkB); and d) functional and health-related
outcomes, i.e., side-effects and medical outcomes, quality of life (QoL), and functional
status.
Inclusion Criteria:
- Histopathologically confirmed prostate cancer
- Elects prostatectomy as first line treatment (i.e., no androgen ablation, radiation
therapy, etc)
- Has at least 3.5 weeks lag-time until scheduled prostatectomy (must be able to
participate in the diet and exercise program a full 3.5 weeks).
- Body mass index (BMI) 25 - 49.9
- Mentally competent
- Able to speak and write English
- Has telephone access
- Agrees to be randomized to either study arm (immediate or delayed diet and exercise
program)
Exclusion Criteria:
- Another active malignancy (not including non-melanoma skin cancer)
- Medical conditions that affect weight (e.g., untreated thyroid disturbances
- Currently on a weight loss regimen
- Preexisting medical condition(s) that preclude adherence to unsupervised exercise,
e.g., severe orthopedic conditions, scheduled for a hip or knee replacement, bone
metastases, paralysis, dementia, untreated stage 3 hypertension, or unstable angina,
heart attack, congestive heart failure or conditions that dictated hospitalization or
oxygen within 6-mths, etc.
We found this trial at
1
site
Click here to add this to my saved trials